The study examined 705 patients with chronic hepatitis B treated with entecavir to determine whether fibrosis at a more advanced stage (Ishak stage 6) was more likely to regress than at stage 5. The results showed that the regression rate of fibrosis was 50.21% at stage 6 compared to 45.58% at stage 5. In multivariable analysis, stage Ishaka 6 associated with a higher probability of fibrosis regression compared to stage 5 (OR: 1.612). This finding is surprising because patients with milder baseline fibrosis have traditionally been thought to have greater potential for improvement. Sensitivity analysis confirmed the consistency of the results (OR: 1.835). The study suggests that Ishak stage 6 patients have a similar or even better potential for fibrosis regression than stage 5 patients with entecavir treatment.